首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1524222

非侵入性幽门螺旋桿菌检测市场- 按测试类型（血清学测试、尿素呼气测试、粪便/粪便抗原测试）、按方法（实验室测试、护理点(POC) 测试）、按最终用途（医院、诊断）实验室）和预测，2024 - 2032

Non-invasive Helicobacter Pylori Testing Market - By Test Type (Serologic Test, Urea Breath Test, Stool/Fecal Antigen Test), By Method (Laboratory Based Test, Point of Care (POC) Test), By End-Use (Hospital, Diagnostic Labs) & Forecast, 2024 - 2032

出版日期: 2024年04月22日 | 出版商:

Global Market Insights Inc. | 英文 105 Pages | 商品交期: 2-3个工作天内

价格

简介目录

随着幽门螺旋桿菌感染发生率的上升，全球非侵入性幽门螺旋桿菌检测市场预计 2024 年至 2032 年复合年增长率将超过 7.1%。 NCBI 的一项研究显示幽门螺旋桿菌感染率为 44.3%。在发展中国家，这一比例为50.8%，高于已开发国家的34.7%。男性感染率为 46.3%，女性感染率为 42.7%。在18岁以上的成年人中，感染率明显较高，为48.6%，而儿童的感染率较低，为32.6%。

将非侵入性幽门螺旋桿菌检测方法整合到日常医疗保健实践中是因为其在无需侵入性操作的情况下诊断幽门螺旋桿菌感染的经过验证的效率，这与医疗保健提供者提高患者舒适度和降低程序风险的目标一致。

由于非侵入性幽门螺旋桿菌检测易于使用并被广泛接受，医疗机构正在将其纳入其标准诊断方案中。这一趋势透过实现及时、准确的诊断来改善患者护理，并增加对非侵入性检测解决方案的需求，显示向高效和以患者为中心的医疗保健实践的更广泛转变。

整个非侵入性幽门螺旋桿菌检测产业根据检测类型、方法、最终用途和地区进行细分。

到 2032 年，尿素呼气测试领域将占据大量非侵入性幽门螺旋桿菌检测市场份额，因为它无需侵入性操作即可有效诊断幽门螺旋桿菌感染。该测试透过测量呼气样本中的二氧化碳含量来检测幽门螺旋桿菌的存在，为内视镜方法提供了一种方便可靠的替代方案。由于医疗保健提供者优先考虑患者的舒适度和成本效益，尿素呼气测试以其简单性和准确性而脱颖而出，推动了其在临床环境中的采用，并促进了非侵入性测试市场的整体增长。

2024 年至 2032 年间，床边 POC 测试领域将在非侵入性幽门螺旋桿菌测试市场上实现显着的复合年增长率。 POC 测试使医疗保健提供者能够在患者床边或门诊环境中快速获得结果，有助于及时做出治疗决策。这种方法透过快速识别幽门螺旋桿菌感染，特别有利于减少週转时间并改善患者的治疗结果。随着医疗机构努力寻求高效的诊断解决方案来提高工作流程和患者满意度，非侵入性 POC 测试的采用不断增长，突显了它们在现代临床实践中的关键作用。

亚太地区非侵入性幽门螺旋桿菌检测市场规模在预测期内将呈现显着的复合年增长率。越来越多的医疗保健服务和有关胃肠道健康的意识计划增加了对有效诊断解决方案的需求。非侵入性检测因其经济实惠和患者舒适度而成为该地区的首选，符合微创手术的文化偏好。此外，亚太地区幽门螺旋桿菌感染的高盛行率凸显了准确且易于使用的检测方法的迫切性。随着医疗保健基础设施的不断改善和诊断技术的进步，幽门螺旋桿菌非侵入性检测的采用将会扩大。

产业生态系统分析
产业影响力
- 成长动力
  - 胃和十二指肠疾病的盛行率上升
  - 对有效抗微生物治疗的需求不断增加
  - 实验室血清学检测的进展
  - 对即时检测设备的需求不断增长
- 产业陷阱与挑战
  - 监理规定严格，幽门螺旋桿菌感染检出率低
成长潜力分析
监管环境
报销场景
技术景观
波特的分析
PESTEL分析
未来市场趋势

第 4 章：竞争格局

介绍
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按测试类型，2021 - 2032 年

主要趋势
血清学检测
尿素呼气试验
粪便/粪便抗原测试

第 6 章：市场估计与预测：依方法，2021 - 2032

主要趋势
基于实验室的测试
护理点 (POC) 测试

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
诊所
诊断实验室
其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Abbott
Biohit Oyj
Bio-Rad Laboratories, Inc.
Cardinal Health
certest Biotech srl
Fisher Scientific
Gulf Coast Scientific
Meridian Bioscience Inc.
Quidel Corporation
Tri-Med

简介目录

Product Code: 9134

Global Non-invasive Helicobacter Pylori Testing Market will infer over 7.1% CAGR between 2024 and 2032, ushered by the rising incidences of H. pylori infections. An NCBI study revealed a 44.3% prevalence of H. pylori infection. In developing nations, the rate stands at 50.8%, higher than the 34.7% observed in developed countries. Men exhibit a predominant infection rate of 46.3% compared to 42.7% in women. Among adults >=18 years, the infection rate is significantly higher at 48.6%, while children show a lower rate of 32.6%.

The integration of non-invasive Helicobacter pylori testing methods into routine healthcare practices is directed by their proven efficiency in diagnosing H. pylori infections without invasive procedures, which aligns with healthcare providers goals of improving patient comfort and reducing procedural risks.

As non-invasive helicobacter pylori tests are accessible and widely accepted, healthcare facilities are incorporating them into their standard diagnostic protocols. This trend improves patient care by enabling timely and accurate diagnosis and boosts demand for non-invasive testing solutions, indicating a broader shift towards efficient and patient-centered healthcare practices.

The overall non-invasive helicobacter pylori testing industry is segmented based on test type, method, end-use, and region.

The urea breath test segment will grab a substantial non-invasive helicobacter pylorus testing market share by 2032 due to its effectiveness in diagnosing H. pylori infections without invasive procedures. This test detects the presence of H. pylori bacteria by measuring carbon dioxide levels in breath samples, offering a convenient and reliable alternative to endoscopic methods. As healthcare providers prioritize patient comfort and cost-efficiency, the urea breath test stands out for its simplicity and accuracy, driving its adoption in clinical settings and contributing to the overall growth of the non-invasive testing market.

The Point-of-Care POC test segment will register a noteworthy CAGR in the non-invasive helicobacter pylori testing market between 2024 and 2032. The Point-of-Care POC test segment is increasing because of its rapid and convenient diagnostic capabilities. POC tests enable healthcare providers to obtain quick results at the patients bedside or in outpatient settings, facilitating timely treatment decisions. This approach is particularly beneficial in reducing turnaround times and improving patient outcomes by swiftly identifying H. pylori infections. As healthcare facilities strive for efficient diagnostic solutions that enhance workflow and patient satisfaction, the adoption of non-invasive POC tests continues to grow, underscoring their pivotal role in modern clinical practice.

Asia Pacific non-invasive helicobacter pylori testing market size will exhibit a noteworthy CAGR during the forecast period. Increasing healthcare access and awareness programs about gastrointestinal health have heightened the need for efficient diagnostic solutions. Non-invasive tests are preferred in this region for their affordability and patient comfort, aligning with cultural preferences for minimally invasive procedures. Additionally, the high prevalence of H. pylori infections in Asia Pacific underscores the urgency for accurate and accessible testing methods. As healthcare infrastructure continues to improve and diagnostic technologies advance, the adoption of non-invasive testing for H. pylori will expand.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of gastric and duodenal illnesses
  - 3.2.1.2 Increasing need for effective anti-microbial treatments
  - 3.2.1.3 Advancements in laboratory serological assay
  - 3.2.1.4 Growing demand for point-of-care testing devices
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Strict regulatory regulations and the low detection rate of H. pylori infection
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Technological landscape
3.7 Porter's analysis
3.8 PESTEL analysis
3.9 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Serologic test
5.3 Urea breath test
5.4 Stool/fecal antigen test

Chapter 6 Market Estimates and Forecast, By Method, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Laboratory based test
6.3 Point of care (POC) test

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Clinics
7.4 Diagnostic laboratories
7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa